2026 Pediatric Rheumatology Symposium

March 18-21, 2026. Minneapolis, MN.

View by Number View by Title View Sessions

Abstract Number: 031

Clinical Characteristics and Diagnostic Predictors of Inflammatory Bowel Disease in Patients with Chronic Nonbacterial Osteomyelitis – A Single Center Retrospective Analysis
Abstract Number: 032

Methotrexate Response in Systemic JIA: Real-World Evidence from a Tertiary-Care Cohort
Abstract Number: 034

Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Cervical Adenitis (PFAPA) Management Across Countries: A Survey to Inform Future Comparative Effectiveness Research
Abstract Number: 035

Healthcare and Medication Utilization Before and After JIA diagnosis in Publicly Insured Children in the United States
Abstract Number: 036

Giant Aneurysms in Kawasaki Disease: A Large Quarternary Single Center Experience
Abstract Number: 037

Off-the-Shelf Anti-CD19 CAR T-cell Therapy with Reduced or No Conditioning Chemotherapy Demonstrates Efficacy and Tolerability in Systemic Lupus Erythematosus: Meaningful Activity Supports Planned Adolescent Enrollment
Abstract Number: 038

Assessment of Disease Activity and Skeletal Damage in Pediatric Chronic Nonbacterial Osteomyelitis and the Effects of Different Treatment Regimens
Abstract Number: 039

Single-center Experience of Voclosporin Use for Pediatric Lupus Nephritis
Abstract Number: 040

Antiphospholipid Antibody-Mediated Disease: Clinical Characteristics and Outcomes of Catastrophic Antiphospholipid Syndrome and Lupus Anticoagulant Hypoprothrombinemia in a Single Center Pediatric Cohort
Abstract Number: 041

Pediatric Behçet’s Disease: A 13-Year Single-Center Experience Highlighting Diagnostic Delays and High Neurological Burden
Abstract Number: 042

Mindfulness Matters: Early Insights from the Making Mindfulness Matter© in children with Juvenile Idiopathic Arthritis Study.
Abstract Number: 043

Challenges of Cognitive Screening and Formal Neuropsychological Evaluation in Youth with Childhood-Onset Systemic Lupus Erythematosus: A Survey of CARRA Providers
Abstract Number: 044

Efficacy of Rituximab Biosimilars in Pediatric ANCA-Associated Vasculitis
Abstract Number: 045

Genotypes and Clinical Phenotypes of Monogenic Autoinflammatory Disorders in Michigan
Abstract Number: 046

Antibiotic Exposure and New Diagnosis of Juvenile Idiopathic Arthritis: A Nested Case-Control Study in a Large US Population

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].